Dipeptidylpeptidase 4 inhibition enhances lymphocyte occurring tumor immunity and immunotherapy

Nature Immunology

16, 850-858

DOI: 10.1038/ni.3201

Citation Report

#	Article	IF	Citations
1	The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis. Frontiers in Immunology, 2015, 6, 387.	2.2	147
2	The Role of Chemokines in Shaping the Balance Between CD4+ T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases. Frontiers in Immunology, 2015, 6, 609.	2.2	46
3	DPP4 in anti-tumor immunity: going beyond the enzyme. Nature Immunology, 2015, 16, 791-792.	7.0	26
4	Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets forMycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases. Clinical Infectious Diseases, 2015, 61, S200-S216.	2.9	33
5	Regulation of Chemokine Activity â€“ A Focus on the Role of Dipeptidyl Peptidase IV/CD26. Frontiers in Immunology, 2016, 7, 483.	2.2	74
6	Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405.		3
7	In Vivo Models to Study Chemokine Biology. Methods in Enzymology, 2016, 570, 261-280.	0.4	4
8	Inhibition of <scp>DPP</scp> 4 activity in humans establishes its inÂvivo role in <scp>CXCL</scp> 10 postâ€translational modification: prospective placeboâ€controlled clinical studies. EMBO Molecular Medicine, 2016, 8, 679-683.	3.3	47
9	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Annals of Oncology, 2016, 27, 1492-1504.	0.6	460
10	Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 127-161.	0.1	0
11	Strategies to Enhance Migration and Persistence of Chimeric Antigen Receptor (CAR)-T Cells into Tumors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 179-193.	0.1	0
12	Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil. Expert Review of Anticancer Therapy, 2016, 16, 1097-1099.	1.1	2
13	Suppression of CD26 inhibits growth and metastasis of pancreatic cancer. Tumor Biology, 2016, 37, 15677-15686.	0.8	8
14	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2016, , .	0.1	2
15	Ultrasensitive Fluorescent Probes Reveal an Adverse Action of Dipeptide Peptidase IV and Fibroblast Activation Protein during Proliferation of Cancer Cells. Analytical Chemistry, 2016, 88, 8309-8314.	3.2	51
16	Response to comment on â€œNRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasisâ€. Science Translational Medicine, 2016, 8, 349lr1.	5.8	8
17	NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science Translational Medicine, 2016, 8, 334ra51.	5.8	182
18	Comment on â€œNRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasisâ€. Science Translational Medicine, 2016, 8, 349le1.	5.8	3

#	Article	IF	Citations
19	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 2016, 44, 1255-1269.	6.6	797
20	TCR-engineered T cells to treat tumors: Seeing but not touching?. Seminars in Immunology, 2016, 28, 10-21.	2.7	62
21	Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy. OncoImmunology, 2016, 5, e1116675.	2.1	9
22	Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. Seminars in Immunology, 2016, 28, 54-63.	2.7	47
23	Expression of recombinant human Î±-lactalbumin in milk of transgenic cloned pigs is sufficient to enhance intestinal growth and weight gain of suckling piglets. Gene, 2016, 584, 7-16.	1.0	11
24	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell, 2016, 29, 285-296.	7.7	349
25	CD26/dipeptidylpeptidase IVâ€"chemokine interactions: double-edged regulation of inflammation and tumor biology. Journal of Leukocyte Biology, 2016, 99, 955-969.	1.5	75
26	Immunotherapy and tumor microenvironment. Cancer Letters, 2016, 370, 85-90.	3.2	242
27	Hepatocellular carcinoma: Mouse models and the potential roles of proteases. Cancer Letters, 2017, 387, 106-113.	3.2	13
28	COX-2 inhibitor prevents tumor induced down regulation of classical DC lineage specific transcription factor Zbtb46 resulting in immunocompetent DC and decreased tumor burden. Immunology Letters, 2017, 184, 23-33.	1.1	27
29	Predicting DPP-IV inhibitors with machine learning approaches. Journal of Computer-Aided Molecular Design, 2017, 31, 393-402.	1.3	24
30	Chemokine Receptor Signaling and the Hallmarks of Cancer. International Review of Cell and Molecular Biology, 2017, 331, 181-244.	1.6	64
31	The proâ€fibrotic role of dipeptidyl peptidase 4 in carbon tetrachlorideâ€induced experimental liver injury. Immunology and Cell Biology, 2017, 95, 443-453.	1.0	32
32	Multimarker risk stratification approach at multiple sclerosis onset. Clinical Immunology, 2017, 181, 43-50.	1.4	9
33	Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2930-2940.	1.8	63
34	Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells. Oncology Letters, 2017, 13, 4224-4230.	0.8	31
35	First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. British Journal of Cancer, 2017, 116, 1126-1134.	2.9	55
36	Combined treatment with dipeptidyl peptidaseâ€4 inhibitor (sitagliptin) and angiotensinâ€II type 1 receptor blocker (losartan) suppresses progression in a nonâ€diabetic rat model of steatohepatitis. Hepatology Research, 2017, 47, 1317-1328.	1.8	22

#	Article	IF	Citations
37	Discovery and validation of a colorectal cancer classifier in a new blood test with improved performance for high-risk subjects. Clinical Proteomics, 2017, 14, 28.	1.1	10
38	Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nature Communications, 2017, 8, 793.	5.8	137
39	Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nature Communications, 2017, 8, 1961.	5.8	67
40	CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. Cell Reports, 2017, 21, 2212-2222.	2.9	83
41	Chemokine isoforms and processing in inflammation and immunity. Journal of Autoimmunity, 2017, 85, 45-57.	3.0	67
42	Improving homing in T cell therapy. Cytokine and Growth Factor Reviews, 2017, 36, 107-116.	3.2	42
43	Immune-Suppressing Cellular Elements of the Tumor Microenvironment. Annual Review of Cancer Biology, 2017, 1, 241-255.	2.3	25
44	DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring. Diabetes, 2018, 67, 518-531.	0.3	56
45	Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling. International Journal of Molecular Sciences, 2017, 18, 1513.	1.8	28
46	Polymicrobial sepsis impairs bystander recruitment of effector cells to infected skin despite optimal sensing and alarming function of skin resident memory CD8 T cells. PLoS Pathogens, 2017, 13, e1006569.	2.1	47
47	Activity and selectivity cliffs for DPPâ€IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening. Medicinal Research Reviews, 2018, 38, 1874-1915.	5.0	32
48	A guide to chemokines and their receptors. FEBS Journal, 2018, 285, 2944-2971.	2.2	748
49	Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine, 2018, 109, 24-28.	1.4	153
50	Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell, 2018, 33, 463-479.e10.	7.7	1,074
51	DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients. Clinical Infectious Diseases, 2018, 66, 45-53.	2.9	89
52	Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2. Cancer Letters, 2018, 420, 26-37.	3.2	37
53	Harnessing Protease Activity to Improve Cancer Care. Annual Review of Cancer Biology, 2018, 2, 353-376.	2.3	70
54	DPPIV/CD26 as a Target in Anti-inflammatory Therapy. , 2018, , 133-147.		1

#	Article	IF	Citations
55	Engineering T cells for adoptive therapy: outsmarting the tumor. Current Opinion in Immunology, 2018, 51, 133-139.	2.4	10
56	Chemokines and cancer: new immune checkpoints for cancer therapy. Current Opinion in Immunology, 2018, 51, 140-145.	2.4	109
57	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation â€“ A target for novel cancer therapy. Cancer Treatment Reviews, 2018, 63, 40-47.	3.4	867
58	Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. International Journal of Cancer, 2018, 142, 1712-1722.	2.3	136
59	A multiâ€‘center retrospective analysis of the effect of DPP4 inhibitors on progressionâ€‘free survival in advanced airway and colorectal cancers. Molecular and Clinical Oncology, 2018, 10, 118-124.	0.4	26
60	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 114.		41
61	Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. PLoS ONE, 2018, 13, e0208225.	1.1	3
62	Statins improve survival in patients previously treated with nivolumab for advanced nonâ€‘small cell lung cancer: An observational study. Molecular and Clinical Oncology, 2018, 10, 137-143.	0.4	39
63	Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4. Clinical and Experimental Immunology, 2018, 194, 166-179.	1.1	53
64	Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Research, 2018, 78, 6354-6362.	0.4	42
65	Immune response biomarkers in human and veterinary research. Comparative Immunology, Microbiology and Infectious Diseases, 2018, 59, 57-62.	0.7	8
66	Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget, 2018, 9, 25808-25825.	0.8	64
67	Intercellular Communication in Tumor Biology: A Role for Mitochondrial Transfer. Frontiers in Oncology, 2018, 8, 344.	1.3	44
68	Dipeptidyl Peptidaseâ€4 Is a Proâ€Recovery Mediator During Acute Hepatotoxic Damage and Mirrors Severe Shifts in Kupffer Cells. Hepatology Communications, 2018, 2, 1080-1094.	2.0	10
69	Structureâ€“Activity Relationship and Molecular Docking of Natural Product Library Reveal Chrysin as a Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: An Integrated In Silico and In Vitro Study. Molecules, 2018, 23, 1368.	1.7	45
70	Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands. Frontiers in Immunology, 2017, 8, 1970.	2.2	227
71	Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Frontiers in Immunology, 2018, 9, 847.	2.2	812
72	Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions. Frontiers in Immunology, 2018, 9, 1456.	2.2	33

#	Article	IF	Citations
73	A novel non-enzymatic hydrolytic probe for dipeptidyl peptidase IV specific recognition and imaging. Chemical Communications, 2018, 54, 8773-8776.	2.2	10
74	Systemic <scp>DPP</scp>4 activity is reduced during primary <scp>HIV</scp>â€1 infection and is associated with intestinal <scp>RORC</scp>⁺<scp>CD</scp>4⁺ cell levels: a surrogate marker candidate of <scp>HIV</scp>â€induced intestinal damage. Journal of the International AIDS Society, 2018, 21, e25144.	1.2	16
75	A novel nbsp role for CD26 dipeptidyl peptidase IV as a therapeutic target. Frontiers in Bioscience - Landmark, 2018, 23, 1754-1779.	3.0	22
76	Recent progresses in small-molecule enzymatic fluorescent probes for cancer imaging. Chemical Society Reviews, 2018, 47, 7140-7180.	18.7	689
77	Immunomodulation of Tumor Vessels: It Takes Two to Tango. Trends in Immunology, 2018, 39, 801-814.	2.9	44
78	Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent. Scientific Reports, 2018, 8, 8959.	1.6	39
79	How post-translational modifications influence the biological activity of chemokines. Cytokine, 2018, 109, 29-51.	1.4	44
80	Differential chemokine receptor expression and usage by preâ€<scp>cDC</scp>1 and preâ€<scp>cDC</scp>2. Immunology and Cell Biology, 2018, 96, 1131-1139.	1.0	24
81	Immunotherapy in CNS cancers: the role of immune cell trafficking. Neuro-Oncology, 2019, 21, 37-46.	0.6	76
82	Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 36-39.	1.8	13
83	Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection. Cancer Immunology Research, 2019, 7, 1440-1456.	1.6	20
84	Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma. Journal of Cancer, 2019, 10, 2578-2587.	1.2	22
85	Inhibition of dipeptidyl peptidase 4 (DPP4) activates immune cells chemotaxis in hepatocellular carcinoma. Oncology Signaling, 2019, 2, 1-3.	0.2	3
86	Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors. Cancer and Metastasis Reviews, 2019, 38, 417-430.	2.7	27
87	Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Lung Cancer, 2019, 137, 64-70.	0.9	10
88	Macrophage chemoattractants secreted by cancer cells: Sculptors of the tumor microenvironment and another crucial piece of the cancer secretome as a therapeutic target. Cytokine and Growth Factor Reviews, 2019, 50, 13-18.	3.2	19
89	The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells, 2019, 8, 613.	1.8	60
90	Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study. Cancer Medicine, 2019, 8, 3918-3927.	1.3	43

#	Article	IF	Citations
91	IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimotoâ€™s thyroiditis. Diagnostic Pathology, 2019, 14, 52.	0.9	10
92	IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. International Journal of Medical Microbiology, 2019, 309, 299-306.	1.5	14
93	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research, 2019, 145, 104258.	3.1	115
94	Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas. Journal of Translational Medicine, 2019, 17, 159.	1.8	40
95	Cryo-thermal therapy inducing MI macrophage polarization created CXCL10 and IL-6-rich pro-inflammatory environment for CD4⁺T cell-mediated anti-tumor immunity. International Journal of Hyperthermia, 2019, 36, 407-419.	1.1	16
96	CD26/DPP4 - a potential biomarker and target for cancer therapy. , 2019, 198, 135-159.		96
97	Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. Frontiers in Immunology, 2019, 10, 333.	2.2	234
98	Origins and clinical relevance of proteoforms in pediatric malignancies. Expert Review of Proteomics, 2019, 16, 185-200.	1.3	12
99	Alarming eosinophils to combat tumors. Nature Immunology, 2019, 20, 250-252.	7.0	18
100	Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nature Immunology, 2019, 20, 257-264.	7.0	144
101	Effects of dipeptidyl peptidaseâ€4 inhibitors on transforming growth factorâ€Î²1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats. Journal of Obstetrics and Gynaecology Research, 2019, 45, 600-608.	0.6	21
102	Effective effectors: How T cells access and infiltrate the central nervous system. , 2019, 197, 52-60.		11
103	Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 115-134.	2.3	70
104	Sodium acetate improves disrupted glucoregulation and hepatic triglyceride content in insulin-resistant female rats: involvement of adenosine deaminase and dipeptidyl peptidase-4 activities. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 103-116.	1.4	5
105	Association of autoimmunity and cancer: An emphasis on proteolytic enzymes. Seminars in Cancer Biology, 2020, 64, 19-28.	4.3	13
106	Deiminated proteins in extracellular vesicles and serum of llama (Lama glama)â€”Novel insights into camelid immunity. Molecular Immunology, 2020, 117, 37-53.	1.0	22
107	Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9. Molecular Therapy - Oncolytics, 2020, 16, 63-74.	2.0	24
108	CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. International Immunopharmacology, 2020, 89, 107043.	1.7	18

#	Article	IF	Citations
109	The immuno-oncological challenge of COVID-19. Nature Cancer, 2020, 1, 946-964.	5.7	96
110	Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer. Journal of Leukocyte Biology, 2020, 108, 673-685.	1.5	26
111	Exploiting proteases for cancer theranostic through molecular imaging and drug delivery. International Journal of Pharmaceutics, 2020, 587, 119712.	2.6	15
112	Role of Chemokines in the Biology of Cholangiocarcinoma. Cancers, 2020, 12, 2215.	1.7	13
113	TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro. Journal of Immunotherapy, 2020, 43, 236-243.	1.2	34
114	Hypoxia Regulates DPP4 Expression, Proteolytic Inactivation, and Shedding from Ovarian Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 8110.	1.8	12
115	Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Molecular Cancer, 2020, 19, 92.	7.9	147
116	Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatology, The, 2020, 2, e437-e445.	2.2	652
117	CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. Frontiers in Immunology, 2020, 11, 976.	2.2	133
118	Targeting Autophagy Facilitates T Lymphocyte Migration by Inducing the Expression of CXCL10 in Gastric Cancer Cell Lines. Frontiers in Oncology, 2020, 10, 886.	1.3	4
119	Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs. Nature Communications, 2020, 11, 1494.	5.8	115
120	CXCL-10: a new candidate for melanoma therapy?. Cellular Oncology (Dordrecht), 2020, 43, 353-365.	2.1	37
121	Deiminated proteins and extracellular vesicles - Novel serum biomarkers in whales and orca. Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2020, 34, 100676.	0.4	19
122	Pleiotropic effects of anti-diabetic drugs: A comprehensive review. European Journal of Pharmacology, 2020, 884, 173349.	1.7	19
123	Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. , 2020, 209, 107503.		136
124	New directions in chimeric antigen receptor T cell [CARâ€T] therapy and related flow cytometry. Cytometry Part B - Clinical Cytometry, 2020, 98, 299-327.	0.7	28
125	Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140409.	1.1	39
126	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity, 2020, 52, 856-871.e8.	6.6	387

#	Article	IF	Citations
127	Sitagliptin affects gastric cancer cells proliferation by suppressing Melanomaâ€associated antigenâ€A3 expression through Yesâ€associated protein inactivation. Cancer Medicine, 2020, 9, 3816-3828.	1.3	21
128	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research, 2020, 26, 487-504.	3.2	355
129	CXCL10 encoding synNotch T cells enhance anti-tumor immune responses without systemic side effect. Biochemical and Biophysical Research Communications, 2021, 534, 765-772.	1.0	6
130	Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 739-762.	2.3	29
131	Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. British Journal of Cancer, 2021, 124, 914-924.	2.9	37
132	What patents tell us about drug repurposing for cancer: A landscape analysis. Seminars in Cancer Biology, 2021, 68, 3-7.	4.3	6
133	Chemokines and Chemokine Receptors. , 2021, , .		1
134	DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers, 2021, 13, 487.	1.7	16
135	Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer. Advanced Science, 2021, 8, 2002497.	5.6	41
136	Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms. Frontiers in Oncology, 2020, 10, 584367.	1.3	8
137	Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells. Biomolecules and Therapeutics, 2021, 29, 154-165.	1.1	5
138	Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?. Cancers, 2021, 13, 1106.	1.7	16
139	From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8. Frontiers in Immunology, 2021, 12, 644725.	2.2	8
140	Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody. Biomarker Research, 2021, 9, 21.	2.8	1
141	Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype. Cell Reports, 2021, 35, 108945.	2.9	38
142	Covalent Small Molecule Immunomodulators Targeting the Protease Active Site. Journal of Medicinal Chemistry, 2021, 64, 5291-5322.	2.9	11
143	The Involvement of the Mammalian Target of Rapamycin, Protein Tyrosine Phosphatase 1b and Dipeptidase 4 Signaling Pathways in Cancer and Diabetes: A Narrative Review. Mini-Reviews in Medicinal Chemistry, 2021, 21, 803-815.	1.1	1
144	The Influence of Anti-Diabetic Drugs on Prostate Cancer. Cancers, 2021, 13, 1827.	1.7	12

#	Article	IF	Citations
145	Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 175.	3.5	24
146	Antidiabetic Agent DPP-4i Facilitates Murine Breast Cancer Metastasis by Oncogenic ROS-NRF2-HO-1 Axis via a Positive NRF2-HO-1 Feedback Loop. Frontiers in Oncology, 2021, 11, 679816.	1.3	4
147	Chemokines and the immune response to cancer. Immunity, 2021, 54, 859-874.	6.6	254
148	Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma. Oncogene, 2021, 40, 3899-3913.	2.6	13
149	Impact of concomitant medication on clinical outcomes in patients with advanced nonâ€small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study. Thoracic Cancer, 2021, 12, 1983-1994.	0.8	26
150	Opening of the Bloodâ€“Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clinical Cancer Research, 2021, 27, 4325-4337.	3.2	58
151	Interaction of long non-coding RNAs and circular RNAs with microRNAs for the regulation of immunological responses in human cancers. Seminars in Cell and Developmental Biology, 2022, 124, 63-71.	2.3	15
152	Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer. Diagnostics, 2021, 11, 1048.	1.3	5
153	Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study. Cancers, 2021, 13, 3588.	1.7	13
154	Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. British Journal of Cancer, 2021, 125, 1068-1079.	2.9	23
155	Dysregulation of DPP4-CXCL12 Balance by TGF-Î²1/SMAD Pathway Promotes CXCR4+ Inflammatory Cell Infiltration in Keloid Scars. Journal of Inflammation Research, 2021, Volume 14, 4169-4180.	1.6	7
156	Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients. Liver Cancer International, 0, , .	0.2	1
157	The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer. Cancers, 2021, 13, 4247.	1.7	8
158	A Single-Chain Variable Fragment Antibody/Chemokine Fusion Protein Targeting Human Endoglin to Enhance the Anti-Tumor Activity of Cytokine-Induced Killer Cells. Journal of Biomedical Nanotechnology, 2021, 17, 1574-1583.	0.5	4
159	Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGFâ€PU.1â€DPP4 Axis. Advanced Science, 2021, 8, e2004673.	5.6	14
160	Antidiabetic DPP-4 Inhibitors Reprogram Tumor Microenvironment That Facilitates Murine Breast Cancer Metastasis Through Interaction With Cancer Cells via a ROSâ€“NF-ÐºBâ€“NLRP3 Axis. Frontiers in Oncology, 2021, 11, 728047.	1.3	8
161	A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer. Current Cancer Drug Targets, 2021, 21, 829-848.	0.8	9
162	A novel method to produce synthetic murine CXCL10 for efficient screening of functional variants. Bioorganic Chemistry, 2021, 116, 105376.	2.0	2

#	Article	IF	Citations
163	Tumor-on-a-chip devices for cancer immunotherapy. , 2022, , 155-195.		1
164	The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review. Inflammatory Bowel Diseases, 2021, 27, 1153-1165.	0.9	4
167	T lymphocytes against solid malignancies: winning ways to defeat tumours. Cell Stress, 2018, 2, 200-212.	1.4	22
168	TILRR (FREM1 isoform 2) is a prognostic biomarker correlated with immune infiltration in breast cancer. Aging, 2020, 12, 19335-19351.	1.4	9
169	DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness. Oncotarget, 2017, 8, 2995-3008.	0.8	24
170	DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis. Oncotarget, 2017, 8, 8679-8692.	0.8	22
171	Mouse CD8+ T Cell Migration in vitro and CXCR3 Internalization Assays. Bio-protocol, 2017, 7, e2185.	0.2	4
172	Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. ELife, 2020, 9, .	2.8	166
173	DOUBLE EDGE EFFECT OF DPP4 INHIBITOR SITAGLIPTIN, A TYPE-2 ANTI-DIABETIC DRUG, ON INFLAMMATION, INJURY AND CANCER. Journal of Stem Cell and Regenerative Biology, 2017, 3, 1-7.	0.2	0
174	Measurement of Dipeptidylpeptidase Activity in vitro and in vivo. Bio-protocol, 2017, 7, e2184.	0.2	1
175	Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. Cancers, 2021, 13, 5367.	1.7	10
176	DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. , 2021, 9, e002837.		23
177	Fueling chimeric antigen receptor T cells with cytokines. American Journal of Cancer Research, 2020, 10, 4038-4055.	1.4	5
178	A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer. Biomolecules, 2021, 11, 1749.	1.8	16
179	Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer. Cancer Research Communications, 2021, 1, 106-114.	0.7	3
180	CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma. Cancers, 2022, 14, 454.	1.7	9
181	Knockdown of DPP4 promotes the proliferation and the activation of the CREB/aromatase pathway in ovarian granulosa cells. Molecular Medicine Reports, 2022, 25, .	1.1	6
182	Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?. Cancers, 2022, 14, 624.	1.7	10

#	Article	IF	Citations
183	Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. Biomedicines, 2022, 10, 284.	1.4	2
184	Chronic kidney disease mediates cardiac dysfunction associated with increased resident cardiac macrophages. BMC Nephrology, 2022, 23, 47.	0.8	3
186	Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2844-2868.	3.3	43
187	Molecular design of near-infrared (NIR) fluorescent probes targeting exopeptidase and application for detection of dipeptidyl peptidase 4 (DPP-4) activity. RSC Chemical Biology, 2022, 3, 859-867.	2.0	5
188	Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity. Nature Immunology, 2022, 23, 568-580.	7.0	18
189	Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease. Frontiers in Immunology, 2022, 13, 830863.	2.2	13
190	The Exploration of Chemokines Importance in the Pathogenesis and Development of Endometrial Cancer. Molecules, 2022, 27, 2041.	1.7	7
191	Cell Trafficking at the Intersection of the Tumorâ€“Immune Compartments. Annual Review of Biomedical Engineering, 2022, 24, 275-305.	5.7	9
192	Distal mutation V486M disrupts the catalytic activity of DPP4 by affecting the flap of the propeller domain. Acta Pharmacologica Sinica, 2022, 43, 2147-2155.	2.8	4
193	Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?. Cancers, 2021, 13, 6317.	1.7	17
195	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. Molecular Therapy - Oncolytics, 2022, 25, 174-188.	2.0	5
199	Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?. Cancers, 2022, 14, 2072.	1.7	19
200	Exploring the potential mechanism of emetine against coronavirus disease 2019 combined with lung adenocarcinoma: bioinformatics and molecular simulation analyses. BMC Cancer, 2022, 22, .	1.1	3
201	Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases. Molecules, 2022, 27, 4498.	1.7	7
202	Incretin based therapy and pancreatic cancer: Realising the reality. World Journal of Gastroenterology, 2022, 28, 2881-2889.	1.4	2
203	Prediction of <scp>DPPâ€IV</scp> Inhibitory Potentials of Polyphenols Existed in Qingke Barley Fresh Noodles: In Vitro and In Silico Analyses. Journal of Food Processing and Preservation, 0, , .	0.9	3
204	The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers, 2022, 14, 3830.	1.7	5
205	Breast cancer cellâ€“derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. Journal of Clinical Investigation, 2022, 132, .	3.9	18

#	Article	IF	Citations
206	The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment. Journal of Immunology Research, 2022, 2022, 1-24.	0.9	4
207	Chemotactic cytokines secreted from Kupffer cells contribute to the sex-dependent susceptibility to non-alcoholic fatty liver diseases in mice. Life Sciences, 2022, 306, 120846.	2.0	6
208	Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease. Scientific Reports, 2022, 12, .	1.6	2
209	Dipeptidyl Peptidase-4 Stabilizes Integrin Î±4Î²1 Complex to Promote Thyroid Cancer Cell Metastasis by Activating Transforming Growth Factor-Beta Signaling Pathway. Thyroid, 2022, 32, 1411-1422.	2.4	9
210	Migratory Engineering of T Cells for Cancer Therapy. Vaccines, 2022, 10, 1845.	2.1	8
211	Induction of pyroptotic cell death as a potential tool for cancer treatment. Journal of Inflammation, 2022, 19, .	1.5	8
212	The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic nonâ€small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 2023, 14, 52-60.	0.8	5
213	Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment. Cells, 2022, 11, 3672.	1.8	15
214	DPP4 Is a Potential Prognostic Marker of Thyroid Carcinoma and a Target for Immunotherapy. International Journal of Endocrinology, 2022, 2022, 1-11.	0.6	2
215	Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma. Cancers, 2023, 15, 272.	1.7	13
216	Dipeptidyl Peptidase 4/Midlineâ€1 Axis Promotes T Lymphocyte Motility in Atherosclerosis. Advanced Science, 2023, 10, .	5.6	2
217	Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia. Experimental Hematology and Oncology, 2023, 12, .	2.0	10
218	Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response. Computers in Biology and Medicine, 2023, 158, 106836.	3.9	1
219	Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. Immunity, 2023, 56, 289-306.e7.	6.6	22
220	Systematic investigation of the mechanism of herbal medicines for the treatment of prostate cancer. Aging, 0, , .	1.4	0
221	A review of the pleiotropic actions of the IFN-inducible CXC chemokine receptor 3 ligands in the synovial microenvironment. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	5
222	Current perspectives of mitochondria-targeted antioxidants in cancer prevention and treatment. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	6
232	CXCL9, CXCL10, CXCL11/CXCR3 Axis and Immune Activation. , 2023, , 271-289.		0

#	Article	IF	Citations
236	How chemokines organize the tumour microenvironment. Nature Reviews Cancer, 2024, 24, 28-50.	12.8	0
237	Hydrogel-mediated tumor T cell infiltration and immune evasion to reinforce cancer immunotherapy. Nanoscale Horizons, 0, , .	4.1	0